NASDAQ · CRBP
Healthcare · Biotechnology
$7.48
Up+$0.22 (+3.03%)
Updated Sep 19, 2026, 9:59 AM
SID Score
2.5/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
CRBP closed at $7.48 after 20 trading sessions, down 27.94% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 18, 2026 | $7.22 | $7.67 | $7.1537 | $7.48 | 1.16M |
| Sep 17, 2026 | $7.26 | $7.38 | $7.03 | $7.26 | 992.87K |
| Sep 16, 2026 | $6.86 | $7.50 | $6.82 | $7.26 | 1.23M |
| Sep 15, 2026 | $8.08 | $8.08 | $6.325 | $6.92 | 3.76M |
| Sep 14, 2026 | $7.93 | $8.70 | $7.66 | $8.08 | 8.4M |
| Sep 11, 2026 | $8.38 | $8.495 | $7.95 | $8.12 | 2.35M |
| Sep 10, 2026 | $8.75 | $8.79 | $8.21 | $8.24 | 646.76K |
| Sep 9, 2026 | $10.60 | $10.715 | $8.845 | $8.86 | 1M |
| Sep 8, 2026 | $11.07 | $11.07 | $10.31 | $10.595 | 915.46K |
| Sep 4, 2026 | $11.37 | $11.445 | $11.055 | $11.08 | 222.61K |
| Sep 3, 2026 | $11.52 | $11.60 | $11.22 | $11.46 | 475.36K |
| Sep 2, 2026 | $11.27 | $11.56 | $10.60 | $11.48 | 664.45K |
| Sep 1, 2026 | $10.81 | $11.37 | $10.575 | $11.28 | 901.3K |
| Aug 31, 2026 | $10.86 | $11.00 | $10.39 | $10.91 | 473.59K |
| Aug 28, 2026 | $11.13 | $11.29 | $10.745 | $10.91 | 584.32K |
| Aug 27, 2026 | $11.28 | $11.45 | $11.11 | $11.13 | 325.89K |
| Aug 26, 2026 | $11.36 | $11.5456 | $10.96 | $11.30 | 392.19K |
| Aug 25, 2026 | $10.90 | $11.35 | $10.79 | $11.31 | 1.28M |
| Aug 24, 2026 | $10.20 | $10.88 | $9.68 | $10.69 | 1.31M |
| Aug 21, 2026 | $9.97 | $10.415 | $9.895 | $10.38 | 604.02K |
The latest Smart Investors Daily articles mentioning CRBP.
CRBP research
Company profile and research snapshot.
Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 14, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 7, 2026 | HC Wainwright & Co. | Buy | — |
| Aug 7, 2026 | Oppenheimer | Outperform | — |
| Jun 23, 2026 | Mizuho | Outperform | — |
| Jun 17, 2026 | Oppenheimer | Outperform | — |
No generated briefing is available yet.
Yahoo · Sep 15, 2026
Corbus Pharmaceuticals (NASDAQ:CRBP) reported top-line results from CANYON-1, a Phase 1b trial evaluating CRB-913, an oral, peripherally restricted CB1 inverse agonist for obesity. The 12-week, placebo-controlled study enrolled 254 patients across 15 U.S. sites, with participants having an average b
Yahoo · Sep 14, 2026
Corbus Pharmaceuticals Holdings Inc. (NASDAQ:CRBP) shares rose 12% on Monday after the company reported topline results from its CANYON-1 Phase 1b clinical trial evaluating CRB-913 as a treatment for obesity.
SeekingAlpha · Sep 14, 2026
Corbus Pharmaceuticals Holdings, Inc. (CRBP) Phase 1b Topline Results for CRB-913 in Obesity and Potential as Weight Loss Therapy September 14, 2026 8:00 AM...
Benzinga · Sep 14, 2026
HC Wainwright & Co. analyst Andres Y. Maldonado reiterates Corbus Pharmaceuticals (NASDAQ:CRBP) with a Buy and maintains $35 price target.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CRBP.
